DALLAS, September 27, 2014 /PRNewswire/ --

MarketOptimizer.org adds PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023 to its store. It says product launches and patent expiries to push major depressive disorder treatment market through fluctuating growth period by 2023. Complete Report Details Available @ http://www.marketoptimizer.org/pharmapoint-major-depressive-disorder-global-drug-forecast-and-market-analysis-to-2023.html .

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The therapeutics market for Major Depressive Disorder (MDD) will face a dynamic phase up until the end of 2023, thanks to the potential launch of new treatments following the patent expirations of top-selling products. According to the latest report "PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023", the MDD treatment market achieved sales of approximately $9.3 billion in 2013 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales will witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a Compound Annual Growth Rate (CAGR) of 0.39%.

However, this major depressive disorder treatment industry report forecasts that the market value will first undergo a decline until 2017, with sales dropping to $7.3 billion. This can be attributed mainly to the expirations of patents for Eli Lilly's Cymbalta, Otsuka Pharmaceutical/BMS' Abilify and AstraZeneca's Seroquel XR. This report provides an overview of Major Depressive Disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis and current treatment options. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the MDD therapeutics market.

Key questions on major depressive disorder treatment market that can get answered through this report include: What will be the impact of imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta and Otsuka/BMS's Abilify in the MDD market? What do physicians think about Lundbeck/Takeda's Brintellix and what will be the impact of its 2014 launch in the MDD market? What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in MDD? What are the significant unmet needs in the MDD market? What are the remaining opportunities in the MDD market?

Key Findings of PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023 research report include: Minimal growth in the MDD market is expected from 2013 to 2023. The key drivers will be the increasing uptake for Lundbeck/Takeda's Brintellix, the potential introduction of seven late-stage pipeline drugs into the MDD market, and the increasing number of prevalent cases of MDD. Key players develop products to broaden and strengthen their portfolios, enter into partnerships for the co-development and co-marketing of products in different regions, and develop products with a novel mechanism of action in order to compete effectively in the crowded depression market. The most pressing unmet need in the depression market is for the development of drugs with improved efficacy. Opportunities remain for products that will meet the significant unmet needs that exist in the MDD market. Products that demonstrate better efficacy, improved safety, and rapid antidepressant effects will move to the forefront of the treatment line.

Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=10716 . (This is a premium report priced at US$10995 for a single user License.)

This report provides overview on following current and future players in major depressive disorder market : Lundbeck, Forest Laboratories (Actavis), Eli Lilly, Pfizer, Otsuka Pharmaceutical, AstraZeneca, Takeda Pharmaceutical, Alkermes, Euthymics Bioscience, Naurex and e-Therapeutics.

Report provides a overview on following product profiles: Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), Savella (Milnacipran), Norepinephrine-Dopamine Reuptake Inhibitors, Noradrenaline and Specific Serotonergic Antidepressants, Monoamine Oxidase Inhibitors, Brintellix (Vortioxetine), Tricyclic Antidepressants, Abilify (Aripiprazole), Seroquel XR (Quetiapine).

Inquire for Discount @ http://www.marketoptimizer.org/contacts/discount?rname=10716 .

(This is a premium report priced at US$10995 for a single user License.)

Scope of PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023 research report include: Overview of MDD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. Annualized MDD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023. Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the MDD therapeutics market. Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs. Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy 

• Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

• Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.

• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MDD therapeutics market in the future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Explore more reports on Pharmaceuticals industry at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals .

About Us:

MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Contact: 

Ritesh Tiwari

TX, Dallas North - Dominion Plaza
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
sales@marketoptimizer.org

SOURCE Market Optimizer